Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus

International Journal of Clinical Rheumatology

Volumn 5, Issue 3, 2010, Pages 313-326

  Achaval, Sofia De ^a   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adherence; Disease modifying antirheumatic drugs; Rheumatoid arthritis; Systematic review; Systemic lupus erythematosus

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

DOCTOR PATIENT RELATION; EDUCATIONAL STATUS; ELECTRONIC MEDICAL RECORD; HEALTH BELIEF; HEALTH CARE COST; HUMAN; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SELF REPORT; SOCIAL STATUS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 77953010289     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.15     Document Type: Review

References (80)

1. Cramer JA, Roy A, Burrell A et al.: Medication compliance and persistence: terminology and definitions. Value Health 11(1), 44-47 (2008).
2. Harrold LR, Andrade SE: Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin. Arthritis Rheum. 38(5), 396-402 (2009).
3. Zolnierek KB, Dimatteo MR: Physician communication and patient adherence to treatment: a meta-analysis. Med. Care. 47(8), 826-834 (2009).
4. Andrade SE, Kahler KH, Frech F, Chan KA: Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 15(8), 565-574 (2006).
5. Masood S, Jayne D, Karim Y: Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus 18(2), 106-115 (2009).
6. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 39(4), 257-268 (2009).
7. Haynes RB, Montague P, Oliver T et al.: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst. Rev. (2), CD000011 (2002).
8. Bruce IN, Gladman DD, Urowitz MB: Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res. 13(6), 406-408 (2000).
9. Darmawan J, Rasker JJ, Nuralim H: Reduced burden of disease and improved outcome of patients with rheumatoid factor positive rheumatoid arthritis compared with dropouts. A 10 year observational study. J. Rheumatol. Suppl. 67, 50-53 (2003).
10. Julian LJ, Yelin E, Yazdany J et al.: Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum. 61(2), 240-246 (2009).
11. Chambers SA, Rahman A, Isenberg DA: Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology 46(6), 895-898 (2007).
12. Melnikow J, Kiefe C: Patient compliance and medical research: issues in methodology. J. Gen. Intern. Med. 9(2), 96-105 (1994).
13. Vermeire E, Hearnshaw H, Van Royen P, Denekens J: Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26(5), 331-342 (2001).
14. Borah BJ, Huang X, Zarotsky V, Globe D: Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr. Med. Res. Opin. 25(6), 1365-1377 (2009).
15. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R: Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 59(10), 1519-1526 (2008).
16. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR: Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med. Care 45(10 Suppl. 2), S66-S76 (2007).
17. Harley CR, Frytak JR, Tandon N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am. J. Manag. Care 9(Suppl. 6) S136-S143 (2003).
18. Koneru S, Shishov M, Ware A et al.: Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 57(6), 1000-1006 (2007).
19. Siva C, Eisen SA, Shepherd R et al.: Leflunomide use during the first 33 months after Food and Drug Administration Approval: experience with a national cohort of 3,325 patients. Arthritis Rheum. 49(6), 745-751 (2003).
20. Osterberg L, Blaschke T: Adherence to medication. N. Engl. J. Med. 353(5), 487-497 (2005).
21. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD: Comparison of methods to assess medication adherence and classify nonadherence. Ann. Pharmacother. 43(3), 413-422 (2009).
22. de Klerk E, Van Der Heijde D, Van Der Tempel H, Van Der Linden S: Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J. Rheumatol. 26(12), 2635-2641 (1999).
23. Butler JA, Peveler RC, Roderick P, Horne R, Mason JC: Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 77(5), 786-789 (2004).
24. Chesney MA, Ickovics JR, Chambers DB et al.: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12(3), 255-266 (2000).
25. Fialko L, Garety PA, Kuipers E et al.: A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr. Res. 100(1-3), 53-59 (2008).
26. Thompson K, Kulkarni J, Sergejew AA: Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr. Res. 42(3), 241-247 (2000).
27. Guénette L, Moisan J, Préville M et al.: Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records. J. Clin. Epidemiol. 58(9), 924-933 (2005).
28. Chambers S, Raine R, Rahman A, Hagley K, De Ceulaer K, Isenberg D: Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 17(8), 761-769 (2008).
29. Chambers SA, Raine R, Rahman A, Isenberg D: Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology 48(3), 266-271 (2009).
30. Sailler L, Puissant B, Méliani P et al.: Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients, Ann. NY Acad. Sci. 1108, 41-50 (2007).
31. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M et al.: Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin. Rheumatol. 27(7), 883-889 (2008).
32. Rojas-Serrano J, Cardiel MH: Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9(8), 601-606 (2000).
33. Ward MM, Lotstein DS, Bush TM, Lambert RE, Van Vollenhoven R, Neuwelt CM: Psychosocial correlates of morbidity in women with systemic lupus erythematosus. J. Rheumatol. 26(10), 2153-2158 (1999).
34. Brus H, Van de Laar M, Taal E, Rasker J, Wiegman O: Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. Patient Educ. Couns. 36(1), 57-64 (1999).
35. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al.: Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66(6), 821-824 (2007).
36. de Klerk E, Van Der Heijde D, Landewé R, Van Der Tempel H, Urquhart J, Van Der Linden S: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J. Rheumatol. 30(1), 44-54 (2003).
37. Dunbar-Jacob J, Holmes JL, Sereika S et al.: Factors associated with attrition of African Americans during the recruitment phase of a clinical trial examining adherence among individuals with rheumatoid arthritis. Arthritis Rheum. 51(3), 422-428 (2004).
38. Evers AW, Kraaimaat FW, Van Riel PL, de Jong AJ: Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain 100(1-2), 141-153 (2002).
39. Fernández-Nebro A, Irigoyen MV, Ureña I: Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J. Rheumatol. 34(12), 2334-2342 (2007).
40. Koneru S, Kocharla L, Higgins GC et al.: Adherence to medications in systemic lupus erythematosus. JCR: J. Clin. Rheumatol. 14(4), 195-201 (2008).
41. Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D: Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum. 47(6), 630-638 (2002).
42. Neame R, Hammond A: Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology 44(6), 762-767 (2005).
43. Horne R, Weinman J: Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 47(6), 555-567 (1999).
44. Treharne GJ, Lyons AC, Kitas GD: Medication adherence in rheumatoid arthritis: Effects of psychosocial factors. Psychol. Health Med. 9(3), 337-349 (2004).
45. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A: Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol. Int. 27(8), 743-746 (2007).
46. Van den Bemt BJ, Van den Hoogen FH, Benraad B, Hekster YA, Van Riel PL, Van Lankveld W: Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J. Rheumatol. 36(10), 2164-2170 (2009).
47. Pincus T: A self-report cognitive symptoms inventory to assess patients with rheumatic diseases: results in eosinophiliamyalgia syndrome (EMS), fibromyalgia, rheumatoid arthritis (RA), and other rheumatic diseases. Arthritis Rheum. 39(Suppl. 9), S261 (1996).
48. Clifford S, Barber N, Horne R: Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. J. Psychosom. Res. 64(1), 41-46 (2008).
49. Johnson MJ: The Medication Adherence Model: a guide for assessing medication taking. Res. Theory Nurs. Pract. 16(3), 179-192 (2002).
50. Wroe AL: Intentional and unintentional nonadherence: a study of decision making. J. Behav. Med. 25(4), 355-372 (2002).
51. Ngoh LN: Health literacy: a barrier to pharmacist-patient communication and medication adherence. J. Am. Pharm. Assoc. (2003) 49(5), E132-E146 (2009).
52. Briesacher BA, Gurwitz JH, Soumerai SB: Patients at-risk for cost-related medication nonadherence: a review of the literature. J. Gen. Intern. Med. 22(6), 864-871 (2007).
53. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M et al.: Determinants of treatment adherence in ethnically diverse, economically disadVantaged patients with rheumatic disease. J. Rheumatol. 32(5), 913-919 (2005).
54. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS: Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am. J. Health Syst. Pharm. 66(16), 1471-1477 (2009).
55. Shi L, Hodges M, Yurgin N, Boye KS: Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). Expert Rev. Pharmacoecon. Outcomes Res. 7(2), 187-202 (2007).
56. Schwartzman S, Morgan GJ Jr: Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res. Ther. 6 (Suppl. 2), S19-S23 (2004).
57. Harrison JA, Mullen PD, Green LW: A meta-analysis of studies of the Health Belief Model with adults. Health Educ. Res. 7(1), 107-116 (1992).
58. Rosenstock IM, Strecher VJ, Becker MH: Social learning theory and the Health Belief Model. Health Educ. Q. 15(2), 175-183 (1988).
59. Nichol MB, Zhang L: Depression and health-related quality of life in patients with rheumatoid arthritis. Expert Rev. Pharmacoecon. Outcomes Res. 5(5), 645-653 (2005).
60. DiMatteo MR: Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 23(2), 207-218 (2004).
61. Uribe AG, Alarcón GS, Sanchez ML: Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum. 51(2), 258-263 (2004).
62. Uribe AG, Ho KT, Agee B et al.: Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: data from the LUMINA cohort. Lupus 13(8), 561-568 (2004).
63. Wong M, Mulherin D: The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Care 5(3), 148-159 (2007).
64. Clifford S, Barber N, Horne R: Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: Application of the Necessity-Concerns Framework. J. Psychosom. Res. 64(1), 41-46 (2008).
65. Kumar K, Gordon C, Toescu V et al.: Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology 47(5), 690-697 (2008).
66. Linde L, Hetland ML, Ãstergaard M: Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand. J. Rheumatol. 35(2), 102-106 (2006).
67. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB: Comparing adherence and persistence across 6 chronic medication classes. J. Manag. Care Pharm. 15(9), 728-740 (2009).
68. Shrank WH, Cadarette SM, Cox E et al.: Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med. Care 47(3), 319-325 (2009).
69. Treharne GJ, Lyons AC, Hale ED, Douglas KM, Kitas GD: 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology 45(1), 1-5 (2006).
70. Elliott RA: Poor adherence to medication in adults with rheumatoid arthritis: reasons and solutions. Dis. Manag. Health Outcomes 16(1), 13-29 (2008).
71. Martin RW, Head AJ, René J et al.: Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: The importance of patient trust of physician. J. Rheumatol. 35(4), 618-624 (2008).
72. Ward MM, Sundaramurthy S, Lotstein D, Bush TM, Neuwelt CM, Street RL Jr: Participatory Patient-Physician Communication and Morbidity in Patients with Systemic Lupus Erythematosus. Arthritis Care Res. 49(6), 810-818 (2003). (Pubitemid 37523634)
73. Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG et al.: Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 55(3), 385-393 (2006).
74. Wolf MH, Putnam SM, James SA, Stiles WB: The Medical Interview Satisfaction Scale: development of a scale to measure patient perceptions of physician behavior. J. Behav. Med. 1(4), 391-401 (1978).
75. Williams A, Manias E, Walker R: Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J. Adv. Nurs. 63(2), 132-143 (2008).
76. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. (2) (2008).
77. Brus HL, Van de Laar MA, Taal E, Rasker JJ, Wiegman O: Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann. Rheum. Dis. 57(3), 146-151 (1998).
78. Hill J, Bird H, Johnson S: Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann. Rheum. Dis. 60(9), 869-875 (2001).
79. Homer D, Nightingale P, Jobanputra P: Providing patients with information about disease-modifying anti-rheumatic drugs: individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. Musculoskeletal Care 7(2), 78-92 (2009).
80. Dunbar-Jacob J, Mortimer-Stephens MK: Treatment adherence in chronic disease. J. Clin. Epidemiol. 54(Suppl. 1), S57-S60 (2001).